Gevokizumab

A4DAB129 | Phase-III

Target IL1B

Isotype / Subclass G2 / None

Company

IRIS National Eye Institute North Shore-Long Island Jewish Health System Novartis Servier University of Zurich XOMA

Clinical Status Phase-III

Format Whole mAb

Synonyms

S-78989 S78989 S 78989 VPM 087 VPM087 VPM-087 VPM87 VPM-87 XMA-005.2 XMA-0052 XMA52 XOMA-052 XOMA052 XOMA52 XOMA-52

pH Formulation —

IMGT PubChem (135322326) PubChem (160704155) PubChem (178103966) PubChem (347911285) PubChem (472220670) PubChem (472390562) PubChem (472435509) PubChem (472439889) PubChem (481155512) PubChem (498155311) PubChem (505635645) Thera-SAbDab YAbS

Avg A4D Score

-0.7168

Score Range

-0.74 to -0.7

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB129_4g6k_H_L	4g6k	100%	-0.6964	6.5	9.0	N/A	N/A
A4DAB129_4g6m_H_L	4g6m	100%	-0.7373	6.5	9.0	N/A	N/A

Gevokizumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2